Skip to content
value.today
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT
$55 Mmarket cap on Oct 30, 2026+40.7% since Jan 2024
Compare
World rank
#20,983
Revenue
—
For year ending December-2025
Net income
$-12 M
SEC filing
Employees
15
As of February 28, 2026
SEC filing

MiNK Therapeutics, Inc. in brief

MiNK Therapeutics, Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its market value was $55 M on 30 October 2026, which makes it the 20,983rd largest listed company in the world and the 3,822nd largest in the USA on this site. It employs about 15 people and Jennifer Buell is its chief executive. Its shares trade under the symbol INKT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is focused on developing innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T cells. Amid a broader industry renaissance in innate immunity—highlighted by surging investment and clinical activity in NK, γδ T, and iNKT-based therapies—iNKT cells represent a distinct T cell population that uniquely bridges innate and adaptive immunity. They combine durable memory responses characteristic of adaptive T cells with rapid, MHC-independent rapid cytolytic capabilities of natural killer cells. This dual functionality enables direct tumor killing via CD1d and stress ligands, potent orchestration of the tumor microenvironment through activation of dendritic cells and NK cells, elimination of immunosuppressive myeloid populations, and restoration of exhausted T-cell function—all while naturally suppressing graft-versus-host disease. This unique combination positions iNKT cells as an optimal platform for allogeneic therapy, given their natural homing capabilities, tumor clearance potential, and efficacy against infected cells.

From the company's annual report filed with the US SEC: read the report

MiNK Therapeutics, Inc. timeline

3 events, 2021
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed MiNK Therapeutics, Inc.
    Formerly AgenTus Therapeutics, Inc..
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 15 October 2021; shares registered for exchange trading on 13 October 2021.

Events of MiNK Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$36 M$72 M$109 M$145 M2023202420252026

World rank over time

▲ up 203 places since 2022
2022-01-07: #21226#21,22620222022-12-25: #22896#22,89620222023-07-30: #24271#24,27120232024-01-05: #26079#26,07920242026-03-08: #10169#10,16920262026-08-01: #19128#19,12820262026-10-09: #20936#20,93620262026-10-30: #21023#21,0232026

Rank in USA: #4,185 (Jan 2022) · #4,469 (Dec 2022) · #4,611 (Jul 2023) · #4,170 (Jan 2024) · #1,972 (Mar 2026) · #3,698 (Aug 2026) · #3,787 (Oct 2026) · #3,826 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
-28.8%
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
199.9%
Profit per employee
$-833 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-16M—FY20Fiscal year ending Dec 2021: revenue —, net income $-30M—FY21Fiscal year ending Dec 2022: revenue —, net income $-28M—FY22Fiscal year ending Dec 2023: revenue —, net income $-22M—FY23Fiscal year ending Dec 2024: revenue —, net income $-11M—FY24Fiscal year ending Dec 2025: revenue —, net income $-12M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-13M$-12M—
Dec 2024——$-11M$-11M—
Dec 2023——$-23M$-22M—
Dec 2022——$-31M$-28M—
Dec 2021——$-28M$-30M—
Dec 2020——$-15M$-16M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-6M——$-2.93—
Dec 2024$-10M——$-2.86—
Dec 2023$-16M$0M$-16M$-6.54—
Dec 2022$-19M$0M$-19M$-0.83—
Dec 2021$-13M$0M$-13M$-1.16—
Dec 2020$-8M$0M$-8M$-0.67—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue —, net income $-3M—Mar ’25Three months to Jun 2025: revenue —, net income $-4M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-3M—Dec ’25Three months to Mar 2026: revenue —, net income $-3M—Mar ’26Three months to Jun 2026: revenue —, net income $-3M—Jun ’26Three months to Sep 2026: revenue $0M, net income $-3M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of MiNK Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-13 M
Net income
$-12 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$14 M
Total liabilities
$28 M
Total equity
$-14 M

As of December-2025

Top 26 institutional investors in MiNK Therapeutics, Inc.#

As of Sep 30, 2026
26 institutions held 194,631 shares (about 3.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 3.8%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in MiNK Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC68,452-208 (-0.30%)1.33%$1 MNov 13, 2026
2DNB Asset Management As43,960-11,182 (-20.28%)0.86%$1 MNov 12, 2026
3Geode Capital Management, LLC18,759+3,186 (+20.46%)0.37%$0 MNov 6, 2026
4Longbow Finance SA16,6670 (0.00%)0.32%$0 MNov 13, 2026
5Vanguard Fiduciary Trust Co13,164+4,877 (+58.85%)0.26%$0 MNov 13, 2026
6BlackRock, Inc.13,074-308 (-2.30%)0.25%$0 MNov 13, 2026
7Bolton Securities Corporation13,0000 (0.00%)0.25%$0 MNov 12, 2026
8Steward Partners Investment Advisory, LLC2,0000 (0.00%)0.04%$0 MNov 13, 2026
9US Bancorp \de\1,9950 (0.00%)0.04%$0 MNov 5, 2026
10UBS Group AG1,462-3,423 (-70.07%)0.03%$0 MNov 10, 2026
11Federation des caisses Desjardins du Quebec750+250 (+50.00%)0.01%$0 MNov 16, 2026
12Paladin Partners, LLC500-500 (-50.00%)0.01%$0 MOct 6, 2026
13Tower Research Capital LLC (TRC)303-119 (-28.20%)0.01%$0 MNov 16, 2026
14Covestor Ltd1190 (0.00%)0.00%$0 MOct 30, 2026
15Morgan Stanley118+5 (+4.42%)0.00%$0 MNov 13, 2026
16Osaic Holdings, Inc.1170 (0.00%)0.00%$0 MNov 12, 2026
17Royal Bank Of Canada72New0.00%$0 MNov 16, 2026
18Wells Fargo & Company/mn26+24 (+1200.00%)0.00%$0 MNov 16, 2026
19Northwestern Mutual Wealth Management Co180 (0.00%)0.00%$0 MNov 13, 2026
20Caitong International Asset Management Co., Ltd180 (0.00%)0.00%$0 MOct 29, 2026
21Game Plan Financial Advisors, LLC160 (0.00%)0.00%$0 MNov 10, 2026
22Clearstead Advisors, LLC140 (0.00%)0.00%$0 MNov 6, 2026
23BNP Paribas Financial Markets130 (0.00%)0.00%$0 MNov 12, 2026
24Jpmorgan Chase & Co90 (0.00%)0.00%$0 MNov 12, 2026
25Key Financial Inc40 (0.00%)0.00%$0 MNov 2, 2026
Show all 26: investors 26 to 26
Institutional investors 26 to 26 in MiNK Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Jones Financial Companies Lllp10 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding MiNK Therapeutics, Inc.#

9 funds hold shares worth $1 M (about 1.7% of the company). Since their previous reports 5 added shares and 1 sold, buying $0 M net.
Mutual funds holding MiNK Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.53,070$1 M1.0%<0.01%+7.7%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.15,382$0 M0.30%<0.01%+53%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC6,599$0 M0.13%<0.01%−0.9%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors6,734$0 M0.13%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC1,902$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC1,883$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,389$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC445$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.208$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at MiNK Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$120 K
9 sales, 2 insiders
Net, 12 months
-$120 K
open market only
Insiders on file
11
since
-$73 K$0Feb 2026: bought $0 (0 trades), sold $4 K (1 trades)Feb 26Mar 2026: bought $0 (0 trades), sold $23 K (5 trades)MarJun 2026: bought $0 (0 trades), sold $19 K (2 trades)JunOct 2026: bought $0 (0 trades), sold $73 K (1 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
MiNK Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jennifer BuellChief Executive Officer, DirectorSell-6,938$10.56$73 K74,195Form 4
filed Jennifer BuellChief Executive Officer, DirectorOption exercise+23,191——81,133Form 4
filed Ulf WiinbergDirectorGrant or award+1,279$10.95$14 K23,929Form 4
filed Barbara RyanDirectorGrant or award+1,622$10.95$18 K23,591Form 4
filed Peter BehnerDirectorGrant or award+1,485$10.95$16 K24,404Form 4
filed Brian CorveseDirectorGrant or award+1,633$10.95$18 K54,770Form 4
filed John Bradley HolcombDirectorGrant or award+1,233$10.95$14 K4,691Form 4
filed Barbara RyanDirectorSell-500$12.68$6 K22,969Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: MiNK Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
55,094
1.2% of shares · 4.29 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split ; 2.783-for-1 split

Trading halts

  • 2025-07-11 14:41 UTC, code LUDP, resumed 14:46 UTC
  • 2025-07-11 14:13 UTC, code LUDP, resumed 14:18 UTC
  • 2025-07-11 14:01 UTC, code LUDP, resumed 14:06 UTC
  • 2025-07-11 13:46 UTC, code LUDP, resumed 13:51 UTC
  • 2025-07-11 13:34 UTC, code LUDP, resumed 13:44 UTC

Fails to deliver

  • : 8 shares at $10.69
  • : 2,025 shares at $10.95
  • : 2,190 shares at $10.71
  • : 935 shares at $10.62
  • : 112 shares at $9.41

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

MiNK Therapeutics, Inc. scorecard#

Passes 2 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-28.8%Free cash flow is -28.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.93 vs -2.86Diluted EPS -2.93 in fiscal 2025 against -2.86 the year before (report's currency).
    • ✓Net income higher than five years earlier-$12 M-$12 M in fiscal 2025 against -$16 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$12 MNet income -$12 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.06 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year13.2%Diluted shares up 13.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

MiNK Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

MiNK Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Research and development5.86.31523149.5
General and administrative6.74.37.47.84.61.3
Operating income−13−11−23−31−28−15
Interest expense and finance costs−0.1−0.1−0.0—2.42.4
Net interest income0.20.20.50.3−2.4—
Other non-operating income (expense)−0.00.3−0.02.70.20.8
Net income including minority interests−12−11−22−28−30−16
Net income attributable to shareholders−12−11−22−28−30−16
Earnings per share, basic-2.93-2.86-6.54r-0.83-1.16-0.67
Earnings per share, diluted-2.93-2.86-6.54r-0.83-1.16-0.67
Shares, weighted average (basic)4.33.83.4r3426—
Shares, weighted average (diluted)4.33.83.4r342624
Balance sheet
Cash and cash equivalents134.63.420392.7
Other current assets0.20.20.20.50.70.9
Current assets145.03.620404.1
Property, plant and equipment0.40.71.01.10.60.5
Total assets145.74.621404.6
Accounts payable3.42.73.95.83.03.1
Current liabilities137.011131614r
Retained earnings−157−144−133−111−83−53
Shareholders' equity−14−20−18−0.424−54r
Total liabilities and equity145.74.621404.6
Shares outstanding4.74.03.5r3433—
Cash-flow statement
Share-based compensation2.71.83.93.01.70.1
Cash from operating activities−5.9−9.6−16−19−13−8.3
Capital expenditure——−0.1−0.3−0.2−0.1
Cash from investing activities——−0.1−0.3−0.2−0.1
Debt issued—————0.4
Cash from financing activities1511−0.4−0.24911
Exchange-rate effect on cash−0.0−0.1−0.00.00.0−0.3
Change in cash8.81.2−16−19362.4
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where MiNK Therapeutics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

MiNK Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at MiNK Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 5 · Material agreement 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 11

MiNK Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Delisting notice8-K
Delisting notice8-K
Results announced8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

H-1B hiring at MiNK Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $109 K a year.

Certified, FY2025
2
#1,610 among companies on value.today
Worker positions
2
Median wage offered
$109 K
a year, full-time
Applications filed
2
MiNK Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Scientist IMolecular and Cellular Biologists1$120 K
Senior Research AssociateMolecular and Cellular Biologists1$98 K

Where: Lexington, MA 2

MiNK Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202522$109 K2
FY202411$120 K1
FY202311$98 K1
FY202111$82 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as MiNK Therapeutics, Inc. and AgenTus Therapeutics, Inc.

How MiNK Therapeutics, Inc. compares in Biotechnology

  • Market cap$55 M · higher than 28% of 726
  • FCF yield-28.8% · higher than 35% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
MiNK Therapeutics, Inc.🇺🇸$55 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of February 28, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at MiNK Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show MiNK Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about MiNK Therapeutics, Inc.? Suggest a correction